Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
GHK-Cu peptide Canada research products are widely used in dermatological and wound healing research models due to the peptides documented interactions with extracellular matrix components and growth factor signaling
no published inhibition or induction data Primary clinical concern / increased bleeding risk from additive vascular and hemostatic effects Severity estimate / moderate (theoretical), based on pharmacodynamic reasoning Monitoring needed / CBC with platelets, PT/INR, anti-Factor Xa levels, signs of bleeding Dose adjustment / no validated protocol exists
FDA peptide decision will illuminate our path forward The FDA is in the midst of deciding whether to allow the seven peptides that were considered by the advisory committee to be compounded by licensed pharmacies
Invoicing in Canadian dollars with the appropriate GST/HST documentation is automatic, and researchers who buy BPC-157 + TB-500 through institutional channels receive the same documentation set as catalogue customers without additional administrative overhead
